Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | MC5R | P33032 | 1/20 | 0.50 |
| ▸ | MC3R | P41968 | 1/20 | 0.50 |
| ▸ | MC1R | Q01726 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641634 | 0.85 | KEAP1 (0.52) | CXCR4NTSR2NTSR1SORT1F13A1 | |
| SCHEMBL30477220 | 0.85 | KEAP1 (0.52) | CXCR4NTSR2NTSR1SORT1F13A1 | |
| SCHEMBL29465231 | 0.85 | CXCR4 (0.56) | CXCR4PCSK9C5AR1OPRD1 | |
| SCHEMBL30436604 | 0.85 | CXCR4 (0.63) | CXCR4 | |
| SCHEMBL31105379 | 0.85 | NPY1R (0.64) | CXCR4C5AR1IL23R | |
| SCHEMBL29973187 | 0.85 | CXCR4 (0.56) | CXCR4C5AR1NTSR2NTSR1SORT1 | |
| SCHEMBL31191176 | 0.84 | C5AR1 (0.64) | CXCR4C5AR1NTSR2NTSR1SORT1 | |
| SCHEMBL29556676 | 0.84 | CXCR4 (0.55) | CXCR4C5AR1NTSR2NTSR1SORT1 | |
| SCHEMBL29800522 | 0.84 | CXCR4 (0.51) | CXCR4PCSK9C5AR1NTSR2NTSR1 | |
| SCHEMBL30216754 | 0.83 | NTSR2 (0.62) | CXCR4C5AR1NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | CASE WESTERN RESERVE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | FN1, IDUA, INHA | CXCR4 1213/4885PCSK9 2143/4885C5AR1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.